Soleus Capital Management, L.P. Bio Atla, Inc. Transaction History

Soleus Capital Management, L.P.

$1.22 Billion
Q1 2024

A detailed history of Soleus Capital Management, L.P. transactions in Bio Atla, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 4,065,197 shares of BCAB stock, worth $6.22 Million. This represents 1.14% of its overall portfolio holdings.

Number of Shares

4,065,197

Previous 4,065,197 -0.0%

Holding current value

$6.22 Million

Previous $10 Million 39.84%

% of portfolio

1.14%

Previous 1.29%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.27 - $3.18 $369,570 - $925,380	-291,000 Reduced 6.68%	4,065,197 $10 Million
Q3 2023 Nov 14, 2023	BUY	$1.7 - $3.07 $59,500 - $107,450	35,000 Added 0.81%	4,356,197 $7.41 Million
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $231,839 - $831,600	100,800 Added 2.39%	4,321,197 $11.6 Million
Q4 2022 Feb 14, 2023	BUY	$7.63 - $11.01 $6.26 Million - $9.03 Million	819,894 Added 24.11%	4,220,397 $34.8 Million
Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $405,132 - $1.64 Million	137,800 Added 4.22%	3,400,503 $26.2 Million

Q2 2022 Aug 15, 2022	BUY	$2.13 - $5.38 $1.59 Million - $4.02 Million	747,279 Added 29.71%	3,262,703 $9.3 Million
Q3 2021 Nov 15, 2021	SELL	$29.44 - $43.74 $8.21 Million - $12.2 Million	-278,809 Reduced 9.98%	2,515,424 $74.1 Million
Q2 2021 Aug 16, 2021	SELL	$38.07 - $56.17 $14.7 Million - $21.6 Million	-385,129 Reduced 12.11%	2,794,233 $118 Million
Q4 2020 Apr 29, 2021	BUY	$31.02 - $35.16 $65.9 Million - $74.7 Million	2,123,805 Added 201.2%	3,179,362 $0
Q4 2020 Feb 16, 2021	BUY	$31.02 - $35.16 $32.7 Million - $37.1 Million	1,055,557 New	1,055,557 $35.9 Million

Others Institutions Holding BCAB

# of Institutions

Shares Held

24.8M

Call Options Held

140K

Put Options Held

4.6K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $55.5M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Soleus Capital Management, L.P. with notifications on news.

Account

Soleus Capital Management, L.P. Bio Atla, Inc. Transaction History